MDT Diabetes

Quote

















































No amount of any new products will save the diabetes division. Too many bad decisions made over the last several years. Competitors took advantage of Medtronic’s horrible leadership and rudderless strategy. Too little and too late.

The best reps have already left. What remains is second and third string back ups that don’t have the talent to win.
 








anonymous said:
No amount of any new products will save the diabetes division. Too many bad decisions made over the last several years. Competitors took advantage of Medtronic’s horrible leadership and rudderless strategy. Too little and too late.

The best reps have already left. What remains is second and third string back ups that don’t have the talent to win.
Click to expand...

^ THIS ^

Except it's not only limited to diabetes, it's ubiquitous across the company. Medtronic has been more concerned with diversity, inclusion, and equity (aka, "DIE") than real business results and the cracks in the company are starting to get very large.
 
























Look at the OU models and products being developed/promoted? Diabetes doesn't really fit into the operating plan, does it? When will Medtronic offload this unpolished turd and call it a day?
 








anonymous said:
Look at the OU models and products being developed/promoted? Diabetes doesn't really fit into the operating plan, does it? When will Medtronic offload this unpolished turd and call it a day?
Click to expand...
To unload it there needs to be a buyer. Who would want this and why? MDT Diabetes hoping for Embecta to save them. Private equity shouldn't touch this. Tandem, Insulet, Dexcom, etc. just laughing.
 








































anonymous said:
Dexcom going to acquire Insulet. Game over. Great job, MDT.
Click to expand...

It's literally only the last few years where Medtronic lost the diabetes market. A series of blunders (most of which could have been avoided) did them in. Of course, when they look in the mirror, they'll wind up seeing somebody else. They'll blame things like "the pandemic" or something else they claim they had no way to respond to. Meanwhile, Dexcom was eating their lunch.
 








Medtronic announces today diabetes revenue down upper 20% range in Q4. Leadership has to own that. No excuses. Plain and simple absolute failure. Guidance for 780 removed from FY23 financials. The ship is not just sinking, it’s completely under water.

EPIC failure to listen to customers and the market. Worst leadership, direction, and strategy. It doesn’t get any worse. Time to unload this business just like J&J did with their pump division. Painful to watch this once dominant division sink to the bottom.
 








What company would acquire the diabetes division? It is so far behind the competition and the newer technology that is yet to be approved looks like it won’t catch up either.
 
















Top Bottom
Back
Quote